6649 Stock Overview
Taiwan Biomaterial Co., Ltd. engages in the development and sale of medical devices in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Taiwan Biomaterial Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$30.00 |
| 52 Week High | NT$44.80 |
| 52 Week Low | NT$24.95 |
| Beta | 0.75 |
| 1 Month Change | -2.44% |
| 3 Month Change | 5.45% |
| 1 Year Change | -26.11% |
| 3 Year Change | 1.35% |
| 5 Year Change | -44.24% |
| Change since IPO | -61.54% |
Recent News & Updates
Shareholder Returns
| 6649 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 0.2% | -0.2% | 1.1% |
| 1Y | -26.1% | 3.4% | 28.2% |
Return vs Industry: 6649 underperformed the TW Medical Equipment industry which returned 3.4% over the past year.
Return vs Market: 6649 underperformed the TW Market which returned 28.2% over the past year.
Price Volatility
| 6649 volatility | |
|---|---|
| 6649 Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in TW Market | 8.8% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6649 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6649's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Wen-Hsi Wang | www.twbm.com.tw |
Taiwan Biomaterial Co., Ltd. engages in the development and sale of medical devices in Taiwan. The company provides Foamagen, a foamy dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and the nickel-titanium guidewire for guiding cerebral vascular surgery; and tissue repair and regeneration products for the treatment of early osteoarthritis. Taiwan Biomaterial Co., Ltd.
Taiwan Biomaterial Co., Ltd. Fundamentals Summary
| 6649 fundamental statistics | |
|---|---|
| Market cap | NT$1.26b |
| Earnings (TTM) | -NT$10.13m |
| Revenue (TTM) | NT$72.84m |
17.3x
P/S Ratio-124.4x
P/E RatioIs 6649 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6649 income statement (TTM) | |
|---|---|
| Revenue | NT$72.84m |
| Cost of Revenue | NT$25.72m |
| Gross Profit | NT$47.12m |
| Other Expenses | NT$57.25m |
| Earnings | -NT$10.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 64.69% |
| Net Profit Margin | -13.91% |
| Debt/Equity Ratio | 0% |
How did 6649 perform over the long term?
See historical performance and comparison